Brookline Capital Management Forecasts CRSP FY2024 Earnings

CRISPR Therapeutics AG (NASDAQ:CRSP) – Brookline Capital Management increased their FY2024 earnings estimates for shares of CRISPR Therapeutics in a research report issued on Monday, January 6th. Brookline Capital Management analyst L. Cann now expects that the company will earn ($5.16) per share for the year, up from their prior forecast of ($5.18). The consensus estimate for CRISPR Therapeutics’ current full-year earnings is ($5.13) per share.

Several other research analysts also recently issued reports on CRSP. Barclays lowered their price objective on CRISPR Therapeutics from $59.00 to $55.00 and set an “equal weight” rating for the company in a research note on Wednesday, November 6th. Chardan Capital reaffirmed a “buy” rating and set a $94.00 price target on shares of CRISPR Therapeutics in a research note on Tuesday, December 10th. Bank of America dropped their price target on shares of CRISPR Therapeutics from $98.00 to $85.00 and set a “buy” rating for the company in a research note on Tuesday. StockNews.com raised shares of CRISPR Therapeutics to a “sell” rating in a research note on Monday, December 30th. Finally, JMP Securities reaffirmed a “market outperform” rating and set a $86.00 target price on shares of CRISPR Therapeutics in a research report on Friday, December 20th. Two investment analysts have rated the stock with a sell rating, eight have assigned a hold rating and ten have assigned a buy rating to the company. According to data from MarketBeat.com, the stock has a consensus rating of “Hold” and a consensus target price of $78.38.

CRISPR Therapeutics Stock Down 1.5 %

NASDAQ CRSP opened at $41.29 on Thursday. The company has a market cap of $3.52 billion, a price-to-earnings ratio of -14.59 and a beta of 1.68. CRISPR Therapeutics has a twelve month low of $38.20 and a twelve month high of $91.10. The business’s fifty day moving average is $46.50 and its 200 day moving average is $48.88.

CRISPR Therapeutics (NASDAQ:CRSP) last posted its earnings results on Tuesday, November 5th. The company reported ($1.01) earnings per share for the quarter, topping analysts’ consensus estimates of ($1.42) by $0.41. The firm had revenue of $0.60 million for the quarter, compared to analysts’ expectations of $6.65 million. CRISPR Therapeutics had a negative net margin of 118.13% and a negative return on equity of 12.15%. During the same quarter in the previous year, the firm posted ($1.41) earnings per share.

Institutional Investors Weigh In On CRISPR Therapeutics

A number of institutional investors and hedge funds have recently bought and sold shares of CRSP. Itau Unibanco Holding S.A. bought a new stake in shares of CRISPR Therapeutics in the 2nd quarter worth $35,000. Wilmington Savings Fund Society FSB purchased a new position in CRISPR Therapeutics during the third quarter worth about $40,000. Darwin Wealth Management LLC bought a new stake in CRISPR Therapeutics in the 3rd quarter worth about $43,000. National Bank of Canada FI increased its stake in CRISPR Therapeutics by 35.0% in the 2nd quarter. National Bank of Canada FI now owns 848 shares of the company’s stock valued at $46,000 after buying an additional 220 shares during the last quarter. Finally, Elkhorn Partners Limited Partnership bought a new position in shares of CRISPR Therapeutics during the 2nd quarter worth approximately $54,000. 69.20% of the stock is owned by hedge funds and other institutional investors.

Insider Buying and Selling

In other CRISPR Therapeutics news, CEO Samarth Kulkarni sold 4,293 shares of the stock in a transaction that occurred on Monday, October 14th. The stock was sold at an average price of $46.28, for a total value of $198,680.04. Following the transaction, the chief executive officer now owns 226,540 shares in the company, valued at approximately $10,484,271.20. This represents a 1.86 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, General Counsel James R. Kasinger sold 1,089 shares of the business’s stock in a transaction that occurred on Monday, October 14th. The shares were sold at an average price of $46.28, for a total value of $50,398.92. Following the sale, the general counsel now owns 62,597 shares of the company’s stock, valued at approximately $2,896,989.16. This represents a 1.71 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 50,382 shares of company stock valued at $2,744,179 over the last ninety days. 4.10% of the stock is owned by corporate insiders.

CRISPR Therapeutics Company Profile

CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases.